Tardive dyskinesia (TD) is one of the most feared side effects of antipsychotic medication — and one of the most under-screened. The good news: new medications approved in the last decade have made TD genuinely treatable for the first time. The bad news: most patients are never asked about it, never screened for it, and never told the new treatments exist.
Tardive dyskinesia is a movement disorder caused by long-term dopamine receptor blockade — usually from antipsychotics — that produces involuntary, repetitive movements that can persist or become permanent if not caught early.
What it looks like
TD typically affects the face and mouth first, but can spread to other parts of the body. Common signs:
- Lip smacking, puckering, or pursing
- Tongue movements — protrusion, twisting, "fly catcher" movements
- Jaw movements — chewing motions, lateral jaw movements
- Eye blinking or grimacing
- Finger movements — like piano playing
- Toe curling, foot tapping
- Trunk movements — rocking, twisting
The movements are involuntary — the person isn't doing them on purpose and often isn't fully aware of them. They typically worsen with stress and disappear during sleep.
Who is at risk
Risk factors include:
- Cumulative antipsychotic exposure — risk rises with years of treatment, roughly 4–8% per year of typical antipsychotic use, lower (1–3%) for second-generation antipsychotics
- Age — older adults are at much higher risk
- Female sex — modestly increased risk
- First-generation antipsychotics (haloperidol, fluphenazine, chlorpromazine) — higher risk than second-generation
- History of acute extrapyramidal symptoms — early movement side effects predict later TD
- Diabetes, mood disorders, intellectual disability — all modestly increase risk
How it's diagnosed
The standard tool is the Abnormal Involuntary Movement Scale (AIMS), a brief structured exam that takes 5–10 minutes. It rates movements in seven body areas plus overall severity. Most psychiatric guidelines recommend an AIMS exam at baseline and at least annually for any patient on long-term antipsychotic medication. In practice, most patients are never given one.
If you're on a long-term antipsychotic, ask your prescriber: "When was my last AIMS exam? Can we do one today?"
What to do if you see signs
1. Don't stop your medication on your own
Counter-intuitively, stopping the antipsychotic can sometimes make TD worse in the short term ("withdrawal dyskinesia") and risks a major psychotic relapse. Always work with a prescriber.
2. Get assessed
An AIMS exam by your prescriber, or a referral to a movement disorder specialist for atypical or severe cases.
3. Consider switching antipsychotics
Switching from a higher-risk antipsychotic (haloperidol, risperidone) to a lower-risk one (clozapine, quetiapine) can reduce or stabilise TD over time.
4. Consider VMAT2 inhibitors
This is the major change in TD treatment. Two FDA-approved medications now treat TD specifically:
- Valbenazine (Ingrezza) — once daily, FDA-approved 2017
- Deutetrabenazine (Austedo) — twice daily with food, FDA-approved 2017
Both reduce TD movements substantially in clinical trials (40–50% reduction). They're the first medications proven to actually treat TD rather than just trying to slow its progression. Both can be taken alongside continued antipsychotic treatment, so you don't have to choose between treating your psychiatric condition and treating your TD.
The honest tradeoff with VMAT2 inhibitors
- Effective — most patients see meaningful reduction
- Expensive — list prices are very high in the US, though insurance and patient assistance programs help
- Side effects are usually mild — sedation, fatigue, sometimes parkinsonism or depression
- Need to be continued — TD movements typically return when the medication is stopped
What about older treatments?
Older approaches with limited evidence include vitamin E (mild possible benefit at preventing progression), Ginkgo biloba (some evidence), benzodiazepines (symptom suppression but tolerance), and amantadine (mixed evidence). None of these are as effective as VMAT2 inhibitors, but they are sometimes used when VMAT2 inhibitors aren't available or affordable.
Will it go away if I stop antipsychotics?
Sometimes. Roughly:
- About 1/3 of cases improve over months to years after stopping or reducing the offending medication
- About 1/3 stabilise but persist
- About 1/3 progress despite reduction
Earlier intervention (catching TD when it's mild and reducing exposure or starting a VMAT2 inhibitor) significantly improves the chance of a good outcome.
What it's not
- Not akathisia — akathisia is a feeling of restlessness; TD is involuntary movement
- Not parkinsonism — parkinsonism is stiffness, slowness, tremor; TD is excessive movement
- Not "just a habit" — although it can look like fidgeting, the movements are involuntary and reflect a real neurological change
Prevention
- Use the lowest effective antipsychotic dose
- Choose second-generation antipsychotics when possible for long-term treatment
- Annual AIMS screening
- Particular vigilance in older patients and those with risk factors
- Re-evaluate the need for ongoing treatment regularly (without stopping abruptly)
The bottom line
TD is real, serious, and historically under-treated. But the picture has changed. With early screening, lower-risk medication choices, and the new VMAT2 inhibitors, most patients today can be effectively treated. The most important step is asking your prescriber to actually look — most diagnoses get missed because no one screens for them.
This article is for educational purposes only and is not medical advice. Always consult your prescribing clinician for personalised guidance.